Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, Randomised, Double-blind, Placebo-controlled Study of the Efficacy of Supplementary Treatment With Cholecalciferol (Vitamin D3) in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Subcutaneous Interferon Beta-1a 44 micrograms 3 Times Weekly.

Next Previous
Trial Profile

A Multicentre, Randomised, Double-blind, Placebo-controlled Study of the Efficacy of Supplementary Treatment With Cholecalciferol (Vitamin D3) in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Subcutaneous Interferon Beta-1a 44 micrograms 3 Times Weekly.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Colecalciferol (Primary) ; Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms CHOLINE
  • Sponsors Merck KGaA

Most Recent Events

  • 08 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 03 Feb 2014 According to the ClinicalTrials.gv record, status changed from recruiting to active, no longer recruiting.
  • 22 Feb 2013 Planned end date changed from 1 Jul 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top